{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:44:27Z","timestamp":1790732667808,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hector Stiftung II gGmbH","award":["MED 1807"],"award-info":[{"award-number":["MED 1807"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib, cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for the application in daily clinical routine has been developed and validated according to the US Food and Drug Administration and European Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples with acetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge\u00ae Phenyl 3.5\u00a0\u03bcm (2.1\u2009\u00d7\u200950\u00a0mm) column. The mobile phases consisted of water-methanol (9:1, v\/v) with 10\u00a0mM ammonium bicarbonate as phase A and methanol-water (9:1, v\/v) with 10\u00a0mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400\u00a0\u03bcL\/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stable isotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0\u00a0min per run. All analytes and internal standards eluted within 3.0\u00a0min. The calibration curves were linear over the range of 2\u2013500\u00a0ng\/mL for afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6\u20131500\u00a0ng\/mL for cabozantinib, dabrafenib, nilotinib, and osimertinib (coefficients of correlation \u2265\u20090.99). Validation assays for accuracy and precision, matrix effect, recovery, carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughput and was successfully applied to monitor concentrations of kinase inhibitors in patients.<\/jats:p>","DOI":"10.1007\/s00216-020-03031-7","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T21:02:59Z","timestamp":1604610179000},"page":"599-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma"],"prefix":"10.1007","volume":"413","author":[{"given":"Fatemeh","family":"Aghai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kurlbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pius","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Isberner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9231","authenticated-orcid":false,"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"3","key":"3031_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971\u20139. https:\/\/doi.org\/10.1124\/jpet.105.084145.","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"3031_CR2","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832\u201342. https:\/\/doi.org\/10.1182\/blood-2013-12-543736.","journal-title":"Blood."},{"key":"3031_CR3","doi-asserted-by":"publisher","unstructured":"Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, et al. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.16979.","DOI":"10.1111\/bjh.16979"},{"issue":"1","key":"3031_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2003.08.004","volume":"50","author":"A Bennasroune","year":"2004","unstructured":"Bennasroune A, Gardin A, Aunis D, Cr\u00e9mel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol. 2004;50(1):23\u201338. https:\/\/doi.org\/10.1016\/j.critrevonc.2003.08.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3031_CR5","unstructured":"EMA-European Medicines Agency. Summary of product characteristics Tagrisso (osimertinib). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tagrisso-epar-product-information_en.pdf. Accessed 22 Sep 2020."},{"key":"3031_CR6","unstructured":"EMA-European Medicines Agency. Summary of product characteristics Giotrif (afatinib). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/giotrif-epar-product-informationen.pdf. Accessed 22 Sep 2020."},{"issue":"8","key":"3031_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692\u2013706. https:\/\/doi.org\/10.1016\/j.ctrv.2009.08.004.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 10","key":"3031_CR8","doi-asserted-by":"publisher","first-page":"S1592","DOI":"10.21037\/tcr.2017.09.10","volume":"6","author":"G Mikus","year":"2017","unstructured":"Mikus G, Foerster KI. Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity. Transl Cancer Res. 2017;6(Suppl 10):S1592\u20139. https:\/\/doi.org\/10.21037\/tcr.2017.09.10.","journal-title":"Transl Cancer Res"},{"issue":"11","key":"3031_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/jcph.526","volume":"55","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Holland J, Mamelok R, Laberge MK, Grenier J, Swearingen D, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293\u2013302. https:\/\/doi.org\/10.1002\/jcph.526.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"3031_CR10","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1053\/j.seminoncol.2011.01.014","volume":"38","author":"J Trent","year":"2011","unstructured":"Trent J, Molimard M. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. Semin Oncol. 2011;38(Suppl 1):S28\u201333. https:\/\/doi.org\/10.1053\/j.seminoncol.2011.01.014.","journal-title":"Semin Oncol"},{"issue":"8","key":"3031_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1177\/0091270009346061","volume":"50","author":"OQP Yin","year":"2010","unstructured":"Yin OQP, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of Nilotinib. J Clin Pharmacol. 2010;50(8):960\u20137. https:\/\/doi.org\/10.1177\/0091270009346061.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3031_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"3031_CR13","doi-asserted-by":"publisher","first-page":"e82562","DOI":"10.1371\/journal.pone.0082562","volume":"8","author":"SC Preissner","year":"2013","unstructured":"Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013;8(12):e82562. https:\/\/doi.org\/10.1371\/journal.pone.0082562.","journal-title":"PLoS One"},{"issue":"2","key":"3031_CR14","doi-asserted-by":"publisher","first-page":"e0003","DOI":"10.1097\/OP9.0000000000000003","volume":"1","author":"C Streicher","year":"2018","unstructured":"Streicher C, Daulange A. Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent: a descriptive study. Eur J Oncol Pharm. 2018;1(2):e0003. https:\/\/doi.org\/10.1097\/OP9.0000000000000003.","journal-title":"Eur J Oncol Pharm"},{"issue":"5","key":"3031_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RWF Van Leeuwen","year":"2013","unstructured":"Van Leeuwen RWF, Brundel DHS, Neef C, Van Gelder T, Mathijssen RHJ, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.48.","journal-title":"Br J Cancer"},{"issue":"8","key":"3031_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/jgs.12942","volume":"62","author":"RJ Maggiore","year":"2014","unstructured":"Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505\u201312. https:\/\/doi.org\/10.1111\/jgs.12942.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"3031_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-016-3145-0","volume":"78","author":"H Kato","year":"2016","unstructured":"Kato H, Sassa N, Miyazaki M, Takeuchi M, Asai M, Iwai A, et al. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2016;78(4):855\u201362. https:\/\/doi.org\/10.1007\/s00280-016-3145-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3031_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40291-017-0292-x","volume":"21","author":"A Nath","year":"2017","unstructured":"Nath A, Wang J, Stephanie HR. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diagn Ther. 2017;21:621\u201331. https:\/\/doi.org\/10.1007\/s40291-017-0292-x.","journal-title":"Mol Diagn Ther"},{"key":"3031_CR19","doi-asserted-by":"publisher","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, et al. The target landscape of clinical kinase drugs. Science. 2017;358(6367). https:\/\/doi.org\/10.1126\/science.aan4368.","DOI":"10.1126\/science.aan4368"},{"issue":"5","key":"3031_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"J Hartmann","year":"2009","unstructured":"Hartmann J, Haap M, Kopp H-G, Lipp H-P. Tyrosine kinase inhibitors \u2013 a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470\u201381. https:\/\/doi.org\/10.2174\/138920009788897975.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"3031_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00228-018-02621-w","volume":"75","author":"R Lasala","year":"2019","unstructured":"Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol. 2019;75(5):697\u2013706. https:\/\/doi.org\/10.1007\/s00228-018-02621-w.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3031_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3816\/CLC.2009.n.039","volume":"10","author":"KSH Nguyen","year":"2009","unstructured":"Nguyen KSH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281\u20139. https:\/\/doi.org\/10.3816\/CLC.2009.n.039.","journal-title":"Clin Lung Cancer"},{"key":"3031_CR23","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","volume":"31","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31:3987\u201396. https:\/\/doi.org\/10.1200\/JCO.2012.45.2029.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3031_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","volume":"78","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2012.06.009.","journal-title":"Lung Cancer"},{"issue":"4","key":"3031_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","volume":"37","author":"HJ Kl\u00fcmpen","year":"2011","unstructured":"Kl\u00fcmpen HJ, Samer CF, Mathijssen RHJ, Schellens JHM, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(4):251\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2010.08.006.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3031_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00280-016-2993-y","volume":"77","author":"D Ouellet","year":"2016","unstructured":"Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, et al. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 2016;77(4):807\u201317. https:\/\/doi.org\/10.1007\/s00280-016-2993-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"3031_CR27","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496\u20139. https:\/\/doi.org\/10.1182\/blood-2006-07-036012.","journal-title":"Blood."},{"key":"3031_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12032-010-9541-0","volume":"28","author":"YYY Zhao","year":"2011","unstructured":"Zhao YYY, Li S, Zhang Y, Zhao HYY, Liao H, Guo Y, et al. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol. 2011;28:697\u2013702. https:\/\/doi.org\/10.1007\/s12032-010-9541-0.","journal-title":"Med Oncol"},{"key":"3031_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/bcp.13327","volume":"83","author":"NAG Lankheet","year":"2017","unstructured":"Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83:2195\u2013204. https:\/\/doi.org\/10.1111\/bcp.13327.","journal-title":"Br J Clin Pharmacol"},{"key":"3031_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:22\u20134028. https:\/\/doi.org\/10.1182\/blood-2007-10-116475.","journal-title":"Blood."},{"key":"3031_CR31","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","volume":"74","author":"V Gotta","year":"2014","unstructured":"Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74:1307\u201319. https:\/\/doi.org\/10.1007\/s00280-014-2599-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3031_CR32","doi-asserted-by":"publisher","unstructured":"Groenland SL, Geel DR, Janssen JM, Beijnen JH, Burgers SA, Smit EF, et al. 1486PD Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients. Ann Oncol. 2019;30(Suppl 5). https:\/\/doi.org\/10.1093\/annonc\/mdz260.008.","DOI":"10.1093\/annonc\/mdz260.008"},{"issue":"2","key":"3031_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/annonc\/mdv538","volume":"27","author":"L Goldwirt","year":"2016","unstructured":"Goldwirt L, Chami I, Feugeas JP, Pages C, Brunet-Possenti F, Allayous C, et al. Reply to \u201cPlasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumour response and tolerance\u201d by Funck-Brentano et al. Ann Oncol. 2016;27(2):363\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdv538.","journal-title":"Ann Oncol"},{"issue":"7","key":"3031_CR34","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/annonc\/mdv189","volume":"26","author":"E Funck-Brentano","year":"2015","unstructured":"Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, et al. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Ann Oncol. 2015;26(7):1470\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdv189.","journal-title":"Ann Oncol"},{"issue":"1","key":"3031_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11523-015-0375-8","volume":"11","author":"N Kramkimel","year":"2016","unstructured":"Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard JL, Noe G, Regnier-Rosencher E, et al. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. Target Oncol. 2016;11(1):59\u201369. https:\/\/doi.org\/10.1007\/s11523-015-0375-8.","journal-title":"Target Oncol"},{"issue":"3","key":"3031_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-019-04002-1","volume":"85","author":"G Kichenadasse","year":"2020","unstructured":"Kichenadasse G, Hughes JH, Miners JO, Mangoni AA, Rowland A, Hopkins AM, et al. Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma. Cancer Chemother Pharmacol. 2020;85(3):615\u201320. https:\/\/doi.org\/10.1007\/s00280-019-04002-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3031_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102(5):765\u201376. https:\/\/doi.org\/10.1002\/cpt.787.","journal-title":"Clin Pharmacol Ther"},{"issue":"32","key":"3031_CR38","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1016\/j.jchromb.2009.10.024","volume":"877","author":"RW Sparidans","year":"2009","unstructured":"Sparidans RW, Iusuf D, Schinkel AH, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877(32):4090\u20136. https:\/\/doi.org\/10.1016\/j.jchromb.2009.10.024.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"10","key":"3031_CR39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1021\/acsmedchemlett.6b00340","volume":"7","author":"B Pinchuk","year":"2016","unstructured":"Pinchuk B, Von Drathen T, Opel V, Peifer C. Photoinduced conversion of antimelanoma agent dabrafenib to a novel fluorescent BRAFV600E inhibitor. ACS Med Chem Lett. 2016;7(10):962\u20136. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00340.","journal-title":"ACS Med Chem Lett"},{"key":"3031_CR40","unstructured":"European Medicines Agency (EMA). European medicines agency guideline on bioanalytical method validation(EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2**). 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 5 Aug 2020."},{"key":"3031_CR41","unstructured":"U.S. Food and Drug Administration (FDA). Bioanalytical method validation guidance. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 5 Aug 2020."},{"issue":"2","key":"3031_CR42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/clinchem\/30.2.290","volume":"30","author":"JS Krouwer","year":"1984","unstructured":"Krouwer JS, Rabinowitz R. How to improve estimates of imprecision. Clin Chem. 1984;30(2):290\u20132. https:\/\/doi.org\/10.1093\/clinchem\/30.2.290.","journal-title":"Clin Chem"},{"key":"3031_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","volume":"150","author":"C Merienne","year":"2018","unstructured":"Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M, et al. High throughput routine determination of 17 tyrosine kinase inhibitors by LC\u2013MS\/MS. J Pharm Biomed Anal. 2018;150:112\u201320. https:\/\/doi.org\/10.1016\/j.jpba.2017.11.060.","journal-title":"J Pharm Biomed Anal"},{"key":"3031_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpba.2018.05.052","volume":"158","author":"R Reis","year":"2018","unstructured":"Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, et al. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc. J Pharm Biomed Anal. 2018;158:174\u201383. https:\/\/doi.org\/10.1016\/j.jpba.2018.05.052.","journal-title":"J Pharm Biomed Anal"},{"key":"3031_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cca.2017.04.009","volume":"470","author":"M Rousset","year":"2017","unstructured":"Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, et al. An UPLC-MS\/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. Clin Chim Acta. 2017;470:8\u201313. https:\/\/doi.org\/10.1016\/j.cca.2017.04.009.","journal-title":"Clin Chim Acta"},{"key":"3031_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jpba.2016.03.049","volume":"125","author":"CM Nijenhuis","year":"2016","unstructured":"Nijenhuis CM, Haverkate H, Rosing H, Schellens JHM, Beijnen JH. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2016;125:270\u20139. https:\/\/doi.org\/10.1016\/j.jpba.2016.03.049.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"3031_CR47","doi-asserted-by":"publisher","first-page":"e4147","DOI":"10.1002\/bmc.4147","volume":"32","author":"M Herbrink","year":"2018","unstructured":"Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, et al. Development and validation of a liquid chromatography\u2013tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr. 2018;32(4):e4147. https:\/\/doi.org\/10.1002\/bmc.4147.","journal-title":"Biomed Chromatogr"},{"key":"3031_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.chemphys.2018.04.006","volume":"507","author":"MS Mirzaei","year":"2018","unstructured":"Mirzaei MS, Taherpour AA. Tautomeric preferences of the cis and trans isomers of axitinib. Chem Phys. 2018;507:10\u20138. https:\/\/doi.org\/10.1016\/j.chemphys.2018.04.006.","journal-title":"Chem Phys"},{"key":"3031_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jchromb.2019.03.011","volume":"1113","author":"GDM Veerman","year":"2019","unstructured":"Veerman GDM, Lam MH, Mathijssen RHJ, Koolen SLW, de Bruijn P. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib. J Chromatogr B Anal Technol Biomed Life Sci. 2019;1113:37\u201344. https:\/\/doi.org\/10.1016\/j.jchromb.2019.03.011.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3031_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jchromb.2016.07.037","volume":"1031","author":"JJM Rood","year":"2016","unstructured":"Rood JJM, van Bussel MTJ, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography\u2013tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1031:80\u20135. https:\/\/doi.org\/10.1016\/j.jchromb.2016.07.037.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"3","key":"3031_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","volume":"56","author":"S Wind","year":"2017","unstructured":"Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet. 2017;56(3):235\u201350. https:\/\/doi.org\/10.1007\/s40262-016-0440-1.","journal-title":"Clin Pharmacokinet"},{"key":"3031_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejca.2018.07.128","volume":"103","author":"CK Lim","year":"2018","unstructured":"Lim CK, Wei YF, Tsai MS, Chen KY, Shih JY, Yu CJ. Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: how low can we go? Eur J Cancer. 2018;103:32\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.128.","journal-title":"Eur J Cancer"},{"key":"3031_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jpba.2019.06.034","volume":"174","author":"JM Janssen","year":"2019","unstructured":"Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. J Pharm Biomed Anal. 2019;174:561\u20136. https:\/\/doi.org\/10.1016\/j.jpba.2019.06.034.","journal-title":"J Pharm Biomed Anal"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-020-03031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-020-03031-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-020-03031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:42:24Z","timestamp":1610592144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-020-03031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s00216-020-03031-7","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Ethics Commission of the University of Wuerzburg (ref199\/18-am) and was conducted in accordance with the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Oliver Scherf-Clavel reports endowed professorship grant (Horphag Research Ltd.). Oliver Scherf-Clavel, Nora Isberner, and Hartwig Klinker received funding for the project \u201cIndividualized cancer therapy with kinase inhibitors using drug monitoring \u2013 optimization by minimally invasive at-home sampling\u201d (Hector Stiftung II gGmbH). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors declare the absence of all other possible conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}